Your browser doesn't support javascript.
loading
Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-κB activation.
Sorrentino, Antonio; Menevse, Ayse Nur; Michels, Tillmann; Volpin, Valentina; Durst, Franziska Christine; Sax, Julian; Xydia, Maria; Hussein, Abir; Stamova, Slava; Spoerl, Steffen; Heuschneider, Nicole; Muehlbauer, Jasmin; Jeltsch, Katharina Marlene; Rathinasamy, Anchana; Werner-Klein, Melanie; Breinig, Marco; Mikietyn, Damian; Kohler, Christian; Poschke, Isabel; Purr, Sabrina; Reidell, Olivia; Martins Freire, Catarina; Offringa, Rienk; Gebhard, Claudia; Spang, Rainer; Rehli, Michael; Boutros, Michael; Schmidl, Christian; Khandelwal, Nisit; Beckhove, Philipp.
Afiliação
  • Sorrentino A; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany Antonio.Sorrentino88@outlook.com beckhove@rcii.de.
  • Menevse AN; Translational Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Michels T; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Volpin V; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Durst FC; Translational Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sax J; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Xydia M; Translational Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hussein A; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Stamova S; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Spoerl S; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Heuschneider N; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Muehlbauer J; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Jeltsch KM; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Rathinasamy A; Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.
  • Werner-Klein M; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Breinig M; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Mikietyn D; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Kohler C; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Poschke I; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Purr S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
  • Reidell O; Signalling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Martins Freire C; Helmholtz-University Group 'Cell Plasticity and Epigenetic Remodeling', German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Offringa R; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Gebhard C; Division of Interventional Immunology, Leibniz Institute for Immunotherapy, Regensburg, Germany.
  • Spang R; Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.
  • Rehli M; Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Boutros M; DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Schmidl C; Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Khandelwal N; Joint Immunotherapeutics Laboratory, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Beckhove P; Research Department, iOmx Therapeutics, Munich/Martinsried, Germany.
J Immunother Cancer ; 10(5)2022 05.
Article em En | MEDLINE | ID: mdl-35606086
ABSTRACT

BACKGROUND:

Cancer immunotherapeutic strategies showed unprecedented results in the clinic. However, many patients do not respond to immuno-oncological treatments due to the occurrence of a plethora of immunological obstacles, including tumor intrinsic mechanisms of resistance to cytotoxic T-cell (TC) attack. Thus, a deeper understanding of these mechanisms is needed to develop successful immunotherapies.

METHODS:

To identify novel genes that protect tumor cells from effective TC-mediated cytotoxicity, we performed a genetic screening in pancreatic cancer cells challenged with tumor-infiltrating lymphocytes and antigen-specific TCs.

RESULTS:

The screening revealed 108 potential genes that protected tumor cells from TC attack. Among them, salt-inducible kinase 3 (SIK3) was one of the strongest hits identified in the screening. Both genetic and pharmacological inhibitions of SIK3 in tumor cells dramatically increased TC-mediated cytotoxicity in several in vitro coculture models, using different sources of tumor and TCs. Consistently, adoptive TC transfer of TILs led to tumor growth inhibition of SIK3-depleted cancer cells in vivo. Mechanistic analysis revealed that SIK3 rendered tumor cells susceptible to tumor necrosis factor (TNF) secreted by tumor-activated TCs. SIK3 promoted nuclear factor kappa B (NF-κB) nuclear translocation and inhibited caspase-8 and caspase-9 after TNF stimulation. Chromatin accessibility and transcriptome analyses showed that SIK3 knockdown profoundly impaired the expression of prosurvival genes under the TNF-NF-κB axis. TNF stimulation led to SIK3-dependent phosphorylation of the NF-κB upstream regulators inhibitory-κB kinase and NF-kappa-B inhibitor alpha on the one side, and to inhibition of histone deacetylase 4 on the other side, thus sustaining NF-κB activation and nuclear stabilization. A SIK3-dependent gene signature of TNF-mediated NF-κB activation was found in a majority of pancreatic cancers where it correlated with increased cytotoxic TC activity and poor prognosis.

CONCLUSION:

Our data reveal an abundant molecular mechanism that protects tumor cells from cytotoxic TC attack and demonstrate that pharmacological inhibition of this pathway is feasible.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: NF-kappa B / Fator de Necrose Tumoral alfa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: NF-kappa B / Fator de Necrose Tumoral alfa Idioma: En Ano de publicação: 2022 Tipo de documento: Article